Medpace Clinical Pharmacology Unit working with HiFiBIO Therapeutics on a SARS-CoV-2 ID-neutralizing antibody for the treatment and prevention of COV19

October 29, 2020

In a recent news release, HiFiBiO Therapeutics announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132 which was conducted in Medpace’s Clinical Pharmacology Unit in Cincinnati, OH. Read More.

Read More